Halozyme Therapeutics, Inc. (HALO) M&A Call Transcript: A Comprehensive Overview

Halozyme Therapeutics has announced a proposed M&A transaction with Elektrofi. The transaction is expected to enhance Halozyme's capabilities in the development and commercialization of innovative drug delivery technologies. The terms of the transaction have not been disclosed.

Halozyme Therapeutics, Inc. (NASDAQ: HALO) has entered into a definitive agreement to acquire Elektrofi, Inc., a Boston-based company specializing in drug delivery technology. The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions and regulatory reviews. The deal is valued at $900 million, comprising an upfront payment of $750 million and up to three $50 million milestone payments contingent on product regulatory approvals Halozyme Therapeutics, Inc. entered into a definitive agreement to acquire Elektrofi, Inc. for $900 million.^[1].

The acquisition will enhance Halozyme's capabilities in the development and commercialization of innovative drug delivery technologies. Elektrofi's Hypercon technology allows for the administration of drug doses at lower injection volumes, facilitating treatment options delivered at home and in outpatient settings. This technology aligns with Halozyme's Enhanze drug delivery technology, promising synergy and growth opportunities Halozyme to acquire Elektrofi, a biopharma focused on drug delivery^[2].

The transaction is expected to increase Halozyme's net leverage to approximately 2X net debt-to-EBITDA immediately following the close. However, the company anticipates rapid deleveraging in subsequent quarters. The acquisition is projected to be less than 5% dilutive to Non-GAAP diluted EPS over the medium term, excluding potential milestone payments related to programs in development Halozyme Therapeutics, Inc. entered into a definitive agreement to acquire Elektrofi, Inc. for $900 million.^[1].

The Boards of Directors of both Halozyme and Elektrofi have unanimously approved the transaction. BofA Securities, Inc. acted as the financial advisor for Halozyme, while Weil, Gotshal & Manges LLP served as the legal advisor. Centerview Partners LLC and Morgan, Lewis & Bockius LLP acted as financial and legal advisors for Elektrofi, respectively Halozyme Therapeutics, Inc. entered into a definitive agreement to acquire Elektrofi, Inc. for $900 million.^[1].